Kyntra Bio to Present at the H.C. Wainwright 28th Annual Global Investment Conference

CEO Thane Wettig’s Sept. 15, 4:00 PM ET presentation will stream live and replay for 90 days via webcast.

Rhea-AI Summary

Kyntra Bio (KYNB) will present at the H.C. Wainwright 28th Annual Global Investment Conference in New York from September 14–16, 2026. CEO Thane Wettig is scheduled to give a company presentation on Tuesday, September 15 at 4:00 PM ET, which will be available via live webcast with a 90-day replay.

Argus Sep 2 session 14 alerts

+7.30% close to close 2.4x rel. volume Open Argus

Details

News Market Reaction – KYNB

+4.2% Peak in 3 hr 33 min

$35.02M Mkt Cap at Peak Alert

On Sep 2, the day this news came out, KYNB closed 7.30% above the previous close. Argus tracked a peak move of +4.2% during that session. Our momentum scanner recorded 14 alerts for this stock that day. Relative volume reached 2.4x the daily average during tracking.

Data tracked by StockTitan Argus for the Sep 2 session.

Key Figures

Conference dates: September 14-16, 2026 Presentation date: September 15, 2026 Presentation time: 4:00 PM ET +3 more

Conference dates

September 14-16, 2026

H.C. Wainwright 28th Annual Global Investment Conference

Presentation date

September 15, 2026

Kyntra Bio company presentation

Presentation time

4:00 PM ET

CEO presentation

Replay availability

90 days

Following the event

Roxadustat trial phase

Phase 3

Anemia associated with lower-risk MDS in the U.S.

FG-3246 development phase

Phase 2

Metastatic castration-resistant prostate cancer

Historical Context

5 past events · Latest: Aug 31

5 events

1. Aug 31

   Royalty financing update

   24h Move

   +2.2%

   Royalty obligations were reduced and remaining payments were capped.

2. Aug 13

   2Q26 earnings report

   24h Move

   +0.1%

   One-time gain offset declining revenue while pipeline enrollment and trial planning continued.

3. Aug 06

   Earnings date notice

   24h Move

   -0.1%

   The company scheduled its second-quarter results release and conference call.

4. Jun 11

   Phase 3 clinical data

   24h Move

   +5.5%

   Roxadustat improved transfusion independence versus placebo in lower-risk MDS.

5. May 11

   1Q26 earnings report

   24h Move

   +6.3%

   Loss narrowed, cash remained substantial, and pipeline development continued.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

antibody-drug conjugate, pet biomarker, chronic kidney disease, myelodysplastic syndrome, +1 more

5 terms

antibody-drug conjugate medical

"a first-in-class antibody-drug conjugate (ADC) targeting CD46"

An antibody-drug conjugate is a targeted medicine that combines an antibody, which can identify specific cells, with a powerful drug designed to destroy those cells. This approach allows for precise treatment, minimizing damage to healthy tissue. For investors, developments in this area can signal advances in cancer therapies and potential growth opportunities in the biotech sector.

pet biomarker medical

"the development of FG-3180, an associated CD46-targeted PET biomarker"

A pet biomarker is a measurable biological sign in an animal—such as a molecule in blood, an image finding, or a physiological reading—that indicates disease presence, progression, or response to treatment. Like a car’s dashboard light that signals a specific problem, these markers can make health status easier to detect and track, which matters to investors because they can enable diagnostic products, guide drug development, reduce trial time and cost, and create commercial services in veterinary and comparative medicine.

chronic kidney disease medical

"anemia in chronic kidney disease (CKD) patients"

Chronic kidney disease is a long-term, progressive loss of kidney function that reduces the organs’ ability to filter waste, control fluid levels and balance body salts. For investors, CKD matters because it creates sustained demand for tests, drugs, dialysis machines and transplants; advances in treatment or regulatory decisions can meaningfully change revenue prospects for companies—like a car that needs ongoing repairs, it creates predictable, long-term market needs.

myelodysplastic syndrome medical

"anemia associated with lower-risk myelodysplastic syndrome (LR-MDS)"

A bone marrow disorder in which the body’s blood-cell “factory” produces too few or abnormal blood cells, leading to anemia, infections, or bleeding and sometimes progressing to acute leukemia. Investors care because the condition creates clinical and commercial opportunities — drugs, tests and treatments that improve blood counts or delay progression can drive regulatory approvals, patient demand and reimbursement decisions, affecting the value of healthcare and biotech companies.

phase 3 trial medical

"evaluate the development plan for the Phase 3 trial"

A Phase 3 trial is a large, late-stage test of a new drug or medical treatment done on many people to make sure it really works and is safe. For investors, it matters because a successful Phase 3 usually means the company can ask regulators to sell the product and could earn lots of money, while failure can sharply reduce the company’s value.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SAN FRANCISCO, Sept. 02, 2026 (GLOBE NEWSWIRE) -- Kyntra Bio (Nasdaq: KYNB) today announced that the company’s management will be attending and presenting at the H.C. Wainwright 28^th Annual Global Investment Conference being held September 14-16, 2026, in New York, NY.

Thane Wettig, Chief Executive Officer of Kyntra Bio, will deliver a company presentation on Tuesday, September 15 at 4:00 PM ET. A live webcast of the presentation will be available here.

Kyntra Bio’s management team will be available for one-on-one meetings during the conference. Interested investors should contact their representative at H.C. Wainwright. The live audio webcast of the event will also be available to investors and other interested parties on the “Events & Presentations” section of the Kyntra Bio Investor webpage at www.kyntrabio.com. The replay will be available for 90 days following the event.

About Kyntra Bio
Kyntra Bio is a biopharmaceutical company focused on development of novel therapies in oncology and rare disease. Roxadustat (爱瑞卓^®, EVRENZO™) is currently approved in Europe, Japan, China, and numerous other countries for the treatment of anemia in chronic kidney disease (CKD) patients on dialysis and not on dialysis. The Company continues to evaluate the development plan for the Phase 3 trial of roxadustat in anemia associated with lower-risk myelodysplastic syndrome (LR-MDS) in the U.S. FG-3246 (also known as FOR46), a first-in-class antibody-drug conjugate (ADC) targeting CD46, is in Phase 2 development for the treatment of metastatic castration-resistant prostate cancer. This program also includes the development of FG-3180, an associated CD46-targeted PET biomarker. For more information, please visit www.kyntrabio.com.

For Investor Inquiries:
David DeLucia, CFA
Senior Vice President and Chief Financial Officer
ir@kyntrabio.com 

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When will Kyntra Bio (KYNB) present at the H.C. Wainwright 28th Annual Global Investment Conference?

Kyntra Bio’s CEO, Thane Wettig, will present on Tuesday, September 15, 2026, at 4:00 PM ET during the H.C. Wainwright 28th Annual Global Investment Conference in New York.

How can investors access the Kyntra Bio (KYNB) presentation webcast from the H.C. Wainwright conference?

A live audio webcast of Kyntra Bio’s presentation will be available via a conference link and in the “Events & Presentations” section of the Kyntra Bio investor webpage at www.kyntrabio.com.

Will a replay of the Kyntra Bio (KYNB) H.C. Wainwright conference presentation be available?

Yes. A replay of the Kyntra Bio presentation audio webcast will be available on the company’s investor webpage for 90 days following the event.

Can investors schedule one-on-one meetings with Kyntra Bio (KYNB) at the H.C. Wainwright 2026 conference?

Yes. Kyntra Bio’s management team will be available for one-on-one meetings during the conference. Interested investors should contact their representative at H.C. Wainwright to arrange meetings.

What does Kyntra Bio (KYNB) focus on in its biopharmaceutical pipeline?

Kyntra Bio focuses on developing novel therapies in oncology and rare disease. Its pipeline includes roxadustat for anemia indications and FG-3246, a CD46-targeting antibody-drug conjugate, along with the FG-3180 CD46-targeted PET biomarker.

What clinical programs of Kyntra Bio (KYNB) are highlighted in this announcement?

The announcement highlights roxadustat, approved in multiple countries for anemia in CKD, with a Phase 3 plan under evaluation for LR-MDS in the U.S., and FG-3246, a first-in-class CD46-targeting ADC in Phase 2 for metastatic castration-resistant prostate cancer, plus the FG-3180 PET biomarker.